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ORIGINAL ARTICLE
Introduction: Xenograft models of epithelial malignancies poten-
tially have greater correlation with clinical end points. We implanted 
153 primary non–small cell lung carcinomas into non-obese dia-
betic-severe combined immunodeficient mice to develop primary 
lung cancer xenografts. Sixty-three xenografts formed. However, in 
19 implantations, tumors consisted of a lymphocyte proliferation 
without a carcinoma component. We further characterized these lym-
phomas to determine clinicopathological features associated with 
their formation.
Methods: Lymphomas were investigated morphologically and 
by silver in situ hybridization to determine their species of ori-
gin. Characterization both of the xenograft lymphomas and 
the primary NSCLCs from which they were derived included 
immunohistochemistry for lymphoma markers and Epstein Barr 
virus Early RNA (EBER) by in situ hybridization. DNA was pro-
filed using the MassARRAY platform; EML4-ALK translocations 
and lymphocyte infiltration were assessed in the primary tumor. 
Lymphoma formation was correlated with patient and primary tumor 
characteristics and survival.
Results: The lymphocytic tumors were EBER positive, human dif-
fuse large B-cell lymphomas (DLBCLs). Significantly more DLBCLs 
that formed in mice arose in primary lung adenocarcinomas and in 
epithelial growth factor receptor mutant never smokers. DLBCL for-
mation was not associated with the degree of tumor-infiltrating lym-
phocytes or EBER-positive lymphocytes in the primary NSCLCs. 
Patients whose tumors developed DLBCL had longer disease-free 
survival compared with patients whose tumors formed epithelial 
xenografts (hazard ratio: 0.44; 95% confidence interval: 0.18 -1.06, 
Wald p = 0.07), regardless of genotype.
Conclusion: We hypothesize that mechanisms involved in the active 
suppression of viral antigens may also be involved in the suppression 
of tumor antigens, and may have resulted in the observed favorable 
clinical outcome.
Key Words: Lymphoma, Primary tumor xenograft, Non–Small-Cell 
Lung Cancer, Survival.
(J Thorac Oncol. 2012;7: 1101–1108)
Improvements in the molecular characterization of tumors and the subsequent development of therapeutic inhibitors of 
specific pathways have relied on tumor models to provide a 
reproducible resource of human tumor tissue. Primary tumor 
xenografts (PTXGs), formed by taking tumor tissue directly 
from a patient and implanting it into an immunocompromised 
host, may have greater clinical correlation than other preclinical 
models. PTXGs have been shown to reproduce features of the 
original tumor both histologically and molecularly,1,2 and have 
been proposed as a tool to predict response to therapies to indi-
vidualize treatment.3–6 Recently, we demonstrated that tumors 
from patients with poorer clinical outcome also are more likely 
to engraft (XG) and grow in immune-compromised murine 
models, suggesting that such tumors are inherently biologically 
more aggressive.1 Furthermore, genomic alterations within 
xenografts have been shown to parallel those of a metastasis 
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rather than the original primary,7 suggesting that engrafting 
tumors may be able to utilize metastasis-specific genomic path-
ways present in the primary tumor to facilitate engraftment.
Immune-compromised hosts are critical for the estab-
lishment and passaging of PTXGs. Several different models 
have been developed in animals with primary immunological 
defects. Because of ease of use, reproducibility, small size, 
and subsequent cost, murine models are used most commonly.8 
Differences in immune function in immunocompromised 
mice range from lack of T-cells in mice with severe combined 
immunodeficiency (scid) to lack of T- and B-cells, impaired 
natural-killer cells, and lack of complement seen in nonobese 
diabetic (NOD)-scid strains. These immune defects can alter 
the engraftability of tumors, but can also increase the risk 
of infection and malignancy in the murine host. Despite the 
absence of T- and B-cells, some levels of immunoglobulin and 
functional immune cells have been reported in these models. 
Interestingly, both scid and NOD-scid mice are susceptible to 
developing de novo thymic lymphomas with age.9,10
Immunological factors have been implicated in the 
clinical outcome of lung cancer patients.11–13 Recent studies 
have demonstrated that infiltrating mature dendritic cells14 
and functional polymorphisms in an innate immunity gene15 
are favorably prognostic in lung cancer patients. Furthermore, 
early studies of ipilimumab, an antibody that potentiates the 
immune response by releasing the cytotoxic T-lymphocyte 
antigen-4 (CTLA-4)/B7 braking system on T-cells, have 
demonstrated improvements in progression-free survival in 
patients with non–small-cell lung carcinomas (NSCLCs).16 
These data highlight the importance of the immune response in 
modulating tumorigenesis, malignant potential, and response 
to treatment. Recent investigations have renewed interest in 
immunological therapies, and signals in the phase 2 setting 
have triggered a number of phase 3 studies.17
We have established PTXGs as models of NSCLC by 
implanting tumors immediately post-resection into the subcuta-
neous tissue of NOD-scid mice.1 These tumors bear closer rep-
resentation to the primary tumors than established cell lines and, 
therefore, may be more clinically applicable. However, not all 
tumors engrafted when implanted. Some rapidly developed into 
large, nonepithelial tumors that morphologically were large cell 
lymphomas. Of these, the majority were found to be of human ori-
gin, with morphology and immunophenotype of DLBCL. Some 
were found to be of mouse origin, with morphology most similar 
to Burkitt lymphoma. Here we detail our characterization of these 
lymphomas, and investigate clinical factors associated with their 
development and their effect on clinical outcomes of patients.
PATIENTS AND METHODS
Patients and Tissue Samples Included
The University Health Network Human Research Ethics 
and Animal Care Committees approved the PTXG protocol as 
previously described.1 Histological classification was based on 
the World Health Organization classification of tumors18 and 
tumor, node, metastasis (TNM) staging was based on the TNM 
classification of the International Union Against Cancer version 
6.19 Tumor-infiltrating lymphocytes (TILs) in the primary tumor 
were evaluated independently by two pathologists after staining 
for CD3 and CD20. The degree of infiltration was classified as 
mild, moderate, and severe. Hematoxylin and eosin staining was 
performed for each tumor at each passage. For the lymphomas, 
a tissue microarray (TMA) was constructed by taking 1.5-mm 
cores from the formalin-fixed paraffin-embedded block and 
arrayed using the Manual Tissue Arrayer (Beecher Instruments, 
Silver Spring, MD). For Epstein Barr Virus (EBV) early RNA 
(EBER) assessment, TMAs were also constructed from the pri-
mary patient tumors using three 0.6-mm cores from the tumor 
tissue and one core from the surrounding normal lung.
Silver In Situ Hybridization and 
Immunohistochemistry Analysis
TMAs were cut at 4 µm thickness and dried in an oven at 
60˚C overnight. The human chromosome 7 specific probe was used 
to distinguish human lymphomas from murine ones. Both immu-
nohistochemistry (IHC) and bright-field silver in situ hybridization 
(SISH) for chromosome 7 were performed using the Ventana auto-
mated stainer, BenchMark XT (Ventana Medical Systems, Tucson, 
AZ), and the Ultraview SISH Detection Kit (Ventana), according 
to the manufacturers’ recommendations. Other antibodies used for 
IHC are listed in Supplementary Table 1 (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A258). Staining for EBER 
was performed on the BenchMark XT using the Ventana Inform 
EBER probe and ISH iView detection kit (Ventana).
Lymphoma markers by IHC were found to be positive (+) 
or negative (−) based on the presence or absence of staining in the 
tumor cells, and distinguishable from nonspecific background 
staining. Infiltrating non-neoplastic inflammatory cells were 
noted in many cases, but their staining was not included in the 
IHC assessment. Clonality was determined by staining for kappa 
and lambda light-chains. For MIB-1, the percentage of stained 
cells was calculated and evaluated as follows: 0% to 33%, low; 
34% to 66%, intermediate; 67% to 100%, high. For EBER, three 
staining patterns were observed: no staining, diffuse staining of 
most or all nuclei, and rare scattered nuclear staining of less than 
1% of cells (most likely small lymphocytes).
Mutational Profiling
Formalin-fixed and paraffin-embedded  tumor blocks of the 
primary tumors were reviewed histologically, and multiple 1.5-mm 
cores were taken from areas of high tumor cellularity, using a TMA 
corer (Beecher Instruments Inc.). DNA was isolated as previously 
described20 and subjected to mass spectrometric profiling for muta-
tional sequence variants using the Sequenom Oncocarta panel 
(Sequenom, Inc., San Diego, CA).21 ALK gene rearrangement 
was detected by standard fluorescence in situ hybridization using 
the Vysis ALK break-apart probe (Abbott Canada, Mississauga, 
Canada), according to the manufacturer’s protocol.22
Statistical Analyses
Primary tumors were classified as those that developed 
human lymphoma, those that engrafted with an epithelial 
tumor, and those that did not engraft (no-XG). Associations 
between these tumor categorizations and various clinical 
parameters were investigated using Fisher’s exact test for 
categorical variables (sex, histology, tumor, node, metastasis 
stage, and smoking status) and the Kruskal-Wallis test for 
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continuous variables (age). Overall survival (OS) and disease-
free survival (DFS) were calculated from the date of surgery 
until the date of death or relapse, or the date of last follow-up 
(updated since our previous report).1 Three-year survival prob-
abilities were calculated using the Kaplan-Meier method and 
differences between the three groups were compared using the 
log-rank test. For mutational correlation, the mutation being 
investigated was excluded from the analyses because of lim-
ited sample size. Cox proportional hazard regression models 
were used to estimate hazard ratios (HR). A two-sided p value 
less than 0.05 was considered to be statistically significant.
RESULTS
Of 153 primary tumors implanted into NOD-scid mice, 
63 engrafted, and formed tumors that could be passaged 
serially (Table 1). Lymphomas were suspected in 24 first-passage 
tumors on the basis of their histological appearances. Using the 
human centrometric enumeration probe 7 (CEP7) probe and SISH 
method, we showed 19 of these lymphomas wto be of human ori-
gin. The specificity of the CEP7 probe was demonstrated by the 
lack of staining of surrounding murine stromal fibroblasts. On 
the basis of SISH, the other five first-passage lymphomas were 
shown to be of murine origin (Fig. 1C,D). Only the 19 human 
lymphomas were subjected to subsequent analyses. The histology 
of the primary NSCLCs that gave rise to a lymphoma was adeno-
carcinoma in 13 of 19 (68%), squamous cell in three (16%), large 
cell in one, mixed small and large-cell neuroendocrine in one, and 
typical carcinoid in the last. More patients whose tumors devel-
oped into lymphomas were lifetime non-smokers, as compared 
to patients whose tumors formed carcinomas or did not engraft 
(42% DLBCLs, 7% XG, 16% No-XG; p < 0.01).
Lymphoma Histology/Morphology
The hematoxylin and eosin sections of the human-de-
rived lymphomas demonstrated sheets of cells that frequently 
contained large, irregular, sometimes lobulated, and pleomor-
phic nuclei with one or more prominent nucleoli. These large 
cells were admixed variably with scattered small lymphocytes, 
histiocytes, and granulocytes (Fig. 1, A,C).
IHC and ISH analysis
Table 2 details the immunophenotyping for the 
19 DLBCLs. Most lymphoma markers showed uniform posi-
tive or negative staining with respect to the malignant-cell 
TABLE 1.  Patient Demographics for Tumor Implantations
Lymphoma 
(n = 19)
no-XG  
(n = 75)
XG 
(n = 59) p Value
0.54
Median age, yrs (range) 69 (52–84) 68 (44–88) 66 (44–84)
Sex: n (%) 0.05
 Female 12 (63) 43 (57) 23 (39)
 Male 7 (37) 32 (43) 36 (61)
Histology: n (%) <0.01
 ADC 13 (68) 53 (71) 28 (48)
 SCC 3 (16) 13 (17) 28 (48)
 Others 3 (16) 9 (12) 3 (4)
TNM Stage: n (%) 0.26
 I–II 14 (74) 62 (83) 42 (71)
 III–IV 5 (26) 13 (17) 17 (29)
Smoking status: n (%) <0.01
 Current/former 11 (58) 58 (77) 51 (86)
 Never 8 (42) 12 (16) 4 (7)
ADC, adenocarcinoma; SCC, squamous-cell carcinoma; NOS, not otherwise specified.
TABLE 2.  Immunohistochemical Results of hLPDs
Antibodies
Case Bcl-2 Bcl-6 CD3 CD5 CD10 CD20 CD23 CD79a LCA L-chain MIB-1
1 + + − − + + − + + Kappa High
2 + − − − − + − + + Lambda Intermediate
3 + − − − − + − + + Kappa Intermediate
4 + + − − − + − + + Lambda High
5 + + − − − + − + + Lambda High
6 + − − − − + − + + Kappa High
7 + − − − − + − + + Kappa High
8 + − − − − + − + + Kappa High
9 + + − − − + − + + Lambda High
10 + − − − − + − + + Kappa High
11 + − − − − + − + + Lambda High
12 + − − − − + − + + Kappa High
13 + − − + − + − + + Kappa High
14 + + − − + + − + + Kappa High
15 + − − − − + − + + Kappa High
16 + + − + − + − + + Kappa High
17 + + − − − + − + + Kappa High
18 + − − − − + − + + Kappa Intermediate
19 + − − − − + − + + Kappa High
L-chain, light-chain; +, positive; −, negative.
1104 Copyright © 2012 by the International Association for the Study of Lung Cancer
John et al. Journal of Thoracic Oncology  •  Volume  7, Number 7, July 2012
FIGURE 1.  Distinguishing human from murine DLBCLs in xenograft specimens. HE stains from a human (A) and murine  
(C) DLBCL. The SISH images (B and D) confirm the presence of human chromosome 7 in B but not D. DLBCL, diffuse large  
B-cell lymphomas; HE, Hematoxylin-Eosin; SISH, silver in situ hybridization.
population. All cases demonstrated diffuse positivity for 
CD45, CD20, and CD79a, and negative staining for CD3, 
thus confirming B-cell lineage (Fig. 2). Only two cases were 
positive for CD10 and seven were positive for bcl-6, 
consistent with a post-germinal center phenotype. All 
cases were positive for bcl-2. Fourteen of 19 lymphomas 
demonstrated kappa light-chain restriction with the remain-
ing five lambda light-chain restricted, indicating clonality. 
Most lymphomas (16 of 19) had a high MIB-1 labeling index, 
whereas the remaining three cases were within the intermedi-
ate range, indicating a high proliferation rate consistent with 
aggressive biology. Two cases were positive for CD5 expression. 
Eighteen of the 19 human-derived lymphomas demonstrated 
diffuse nuclear staining of all tumor cells for EBER. Thus, these 
DLBCLs had an immunophenotype similar to that seen in EBV 
positive post-transplant lymphoproliferative disease.
Association of DLBCL Formation and TILs
We hypothesized that the DLBCLs may have formed 
stochastically as a result of a large primary tumor TIL popula-
tion being transferred into an immunosuppressed environment. 
All primary implanted tumors were scored for the degree of 
lymphocyte infiltration. We compared epithelial XGs, tumors 
that formed DLBCLs, and those that did not engraft. There was 
no significant increase in TILs in DLBCL-forming tumors com-
pared with engrafting epithelial and non-engrafting tumors.
Association of DLBCL Formation and EBV 
Positive Lymphocyte Presence in Primary 
Tumors
All 153 primary tumors, including those that gave rise to 
DLBCLs, were stained for EBER. EBV protein was detected 
in all the DLBCLs but not in any lymphocytes of the primary 
tumors from which they were derived. In total, only eight of 
the 153 primary tumors stained positively for EBER. Diffuse 
staining of the tumor cells was seen in three primary tumors 
that were of lymphoepithelioma-like subtype. Interestingly, 
none of these tumors gave rise to a xenograft lymphoma. 
Five further cases (three adenocarcinomas and two squamous-cell 
carcinomas) showed EBER positive lymphocytes. Two of these 
latter five cases gave rise to passagable epithelial XG, whereas the 
other three did not engraft and did not form DLBCLs. Although 
it is possible that some tumors showing scattered positive lym-
phocytes may have been missed because of sampling errors of 
the TMA, these findings suggest that the degree of EBER posi-
tive B-lymphocyte infiltration within the primary tumor does not 
correlate with the formation of DLBCLs.
Correlation of EML4-ALK Rearrangements, 
Mutations, and Lymphoma Formation
Of 153 primary tumors, adequate DNA was retrievable in 
142 samples. Results for mutational analysis are summarized 
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in Table 3. Three tumors in the DLBCL group harbored no 
mutations. Activating mutations in the epithelial growth fac-
tor receptor (EGFR) gene were found in six of 19 tumors. In 
the DLBCL group, all of the EGFR mutations were detected 
in non-smokers. KRAS mutations were detected in seven of 
19 tumors. EML4-ALK rearrangement was detected in one 
adenocarcinoma that did not engraft.
Correlation of DLBCL With Clinical Outcome
Given prior literature demonstrating that the immuno-
logical features of primary tumors may be associated with 
favorable clinical outcome, we investigated the outcomes of 
patients whose tumors formed DLBCLs and compared them 
with those whose tumors established epithelial XGs or did 
not engraft. DLBCL patients had longer DFS (HR 0.44 95% 
CI 0.18–1.06; Wald p value = 0.07) compared to patients 
whose tumors engrafted with passagable carcinoma 
(Fig. 3A). DFS in the DLBCL group was similar to that 
of patients whose tumors did not engraft. Furthermore, 
given that 13 of 19 DLBCLs were derived from 
primary adenocarcinomas, when comparing only patients 
with adenocarcinoma, DFS also was significantly 
longer (HR 0.12; 95% CI 0.03–0.53; Wald p value < 0.01, 
FIGURE 2.  Representative images of DLBCL IHC for one case. CD20 (A), CD79a (B), CD3 (C), kappa light chain (D), lambda 
light chain (E), and MIB-1 (F). DLBCL, diffuse large B-cell lymphomas; IHC, immunohistochemistry.
TABLE 3. Results of Mutational Analysis for 142 Samples
Lymphoma (n = 18) No-XG (n = 69) XG (n = 55) Overall p Value*
None: n (%) 3 (17) 36 (52) 34 (62) 73
BRAF: n (%) 0 (0) 0 (0) 1 (2) 1
EGFR: n (%) 6 (33) 11 (16) 2 (4) 19 0.02
HRAS: n (%) 0 (0) 1 (1) 0 (0) 1
KRAS: n (%) 7 (39) 13 (19) 13 (24) 33 0.13
MET: n (%) 1 (6) 6 (9) 2 (4) 9
PIK3CA: n (%) 1 (6) 2 (3) 3 (5) 6
*Fisher’s exact test comparing lymphoma to no-XG and XG.
No-XG, non-engraft; XG, engraft; EGFR, epithelial growth factor receptor.
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FIGURE 3.  Kaplan-Meier disease-free and overall survival curves comparing all XG, no-XG, and diffuse large B-cell lymphoma 
(DLBCL) groups (A and C) and those with adenocarcinoma lung primaries (B and D) demonstrating improved disease-free sur-
vival (DFS) and a trend toward overall survival in the DLBCL patients compared with XG patients. DFS in patients wild-type for 
EGFR in the entire cohort (E) and in the group with adenocarcinoma (F). DLBCL, diffuse large B-cell lymphomas; XG, xenograft; 
no-XG, non-engrafting.
Fig. 3C). The median OS has not been reached for any group 
(Fig. 3B). However, compared to patients whose tumors 
developed epithelial xenografts, trends toward longer OS 
were seen for patients whose tumors did not engraft (HR 
0.37 95% CI 0.15–0.89; p = 0.03) and also for patients whose 
tumors gave rise to DLBCLs (HR 0.55 95% CI 0.16–1.92; 
p = 0.35). Similar results were seen for adenocarcinoma (HR 
0.25 95% CI 0.03–2.2; p = 0.21, Fig. 3D).
As EGFR mutations are known to be favorably 
prognostic,23 we investigated whether the survival differences 
seen in the DLBCL group was attributable to those patients 
with EGFR mutant tumors. Disease-free and OS remained 
similar when these patients were excluded from the analy-
sis (Fig. 3E). In patients whose EGFR wild-type adenocar-
cinoma primary tumor developed DLBCL, there remained a 
significant improvement in DFS when compared to engraft-
ing EGFR wild-type tumors (HR 0.17 95% CI 0.04–0.78, 
p = 0.022, Fig. 3F). These data support the observation that 
the survival differences in the DLBCL group were not driven 
by EGFR mutant tumors.
DISCUSSION
Investigators involved in xenografting primary tumors 
have long recognized that some implanted tumors develop 
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rapidly into lymphomas that are passagable but without an epi-
thelial component. These have been mentioned as a potential 
limiting factor of immunosuppressed murine models;24 how-
ever, we could find no studies that comprehensively character-
ized these tumors and correlated their presence with clinical 
parameters. We sought to clarify initially whether the tumors 
were human or murine in cell type, to investigate their asso-
ciation with TILs and EBV and to determine whether these 
patients had clinical outcomes that were different from those 
whose epithelial tumors engrafted. We have demonstrated that 
all the lymphomas that developed in the initial implantation 
step were of human origin and were EBV positive; they arose 
predominantly from adenocarcinoma implantations, and were 
not associated with increased frequency of TILs or the pres-
ence of EBV positive lymphocytes within the primary tumor. 
Importantly, the patients whose tumors gave rise to these 
DLBCLs had significantly longer DFS when compared to 
those whose epithelial tumors engrafted.
Several factors could potentially be associated with the 
formation of DLBCLs in these models. The NOD-scid and 
scid models are prone to the development of de novo thymic 
lymphomas of murine origin, but not other lymphomas. As 
all lymphomas that developed in our study were EBV posi-
tive, a link between this known lymphomagenic virus and the 
DLBCLs was postulated. However, EBER expression was not 
detected in the primary tumors of the same samples. None of 
the DLBCL samples had significantly more B- or T-cell TILs 
than the other 134 samples that did not form lymphomas. 
Taken together, this suggests that the numbers of lymphocytes 
in the primary tumor, with or without latent EBV infected 
lymphocytes, were not associated with DLBCL formation.
EBV commonly causes primary infection in most peo-
ple at a young age such that it is nearly ubiquitous in healthy 
adults. EBV has been shown previously to be associated with 
the formation of DLBCLs in immunosuppressed mice,25–27 
and is known to cause human lymphomas in immunosup-
pressed patients. Three clinically and histologically distinct 
EBV-associated B-cell lymphomas are known: (1) lymphoma 
associated with immunosuppression (2) Hodgkins lymphoma, 
and (3) Burkitt’s lymphoma. Patients with T-cell immunosup-
pression, such as those with post-transplantation or those with 
acquired immunodefficiency syndrome are at increased risk 
of developing EBV-associated lymphomas. These lympho-
mas are similar in morphology and immunophenotype to the 
lymphomas described in our NOD-scid population. Technically, 
this environment parallels that seen in the immediate 
post-transplant setting when T-Cell immunosuppression 
is usually kept at high levels to prevent graft rejection. 
Approximately 40% of Hodgkin’s lymphomas in the devel-
oped world are associated with EBV.28 In these lymphomas, 
the viral genome is present in every Reed-Sternberg cell, 
and expresses a subset of latent-cycle proteins.28 In endemic 
Burkitt’s lymphoma, EBV is present in all cases. In the devel-
oping world, Burkitt’s lymphoma is also common among car-
riers of the human immunodeficiency virus, even in those who 
are relatively immunocompetent. None of the human lym-
phomas that developed in our study displayed morphologi-
cal or immunophenotypic features of Burkitt’s or Hodgkin’s 
lymphoma.
The association of DLBCL formation with favorable 
clinical outcome is intriguing, especially as it was indepen-
dent of activating mutations in the EGFR gene, a known 
favorable prognostic factor. As EBV is ubiquitous, and all 
our DLBCLs expressed EBV RNA, we had expected the 
lymphocytes within the primary tumors also to stain posi-
tively for EBER. EBER is present in both the latent and 
active phase of EBV infection. Therefore, these results sug-
gest that latent EBV infected B-cells were tightly controlled 
in the human host, such that their presence was undetect-
able. Latently infected B-cells maintain the lifelong virus-
carrier state, and EBV-associated diseases can be divided 
based on the latent antigen repertoire that is expressed.29 By 
recognition of epitopes within the latent, lytic, and struc-
tural components of the virus, cytotoxic T lymphocytes 
(CTLs) play a critical role in limiting the expansion of 
infected B-cells.30,31 T-cells are more difficult to culture ex-
vivo, and so it is possible that any CTLs present within the 
primary tumor were unable to proliferate in the NOD-scid 
environment. When CTL response is dampened through 
either immunosuppression or, in this case, xenotransplanta-
tion into an immunosuppressed host, the latently infected 
B-cells are able to proliferate unchecked. A similar envi-
ronment exists in EBV-associated post-transplant lymphop-
roliferative disorders where T-cell suppression unmasks 
the disease. Taken together, the prolonged survival in our 
patients who developed EBV positive DLBCLs may indi-
cate improved CTL response not only to viral antigens but 
also to tumor antigens.
The use of immunotherapy in the treatment of lung can-
cer is being explored increasingly.32 To date, although several 
vaccination strategies seemed to be promising in small phase 
2 trials in lung cancer, many have failed to demonstrate clini-
cal benefit in their randomized phase 3 confirmatory trials; 
however, several large studies are still underway.17 In recent 
clinical studies, abrogating T-cells by blockade of the CTLA-4/
B7 brake with ipilimumab, thereby stimulating the immune 
response to tumor antigens, has shown promise in a phase 2 
study,16 and ipilimumab has now entered into phase 3 trials 
in both small cell and non–small cell lung cancer. Similar 
strategies in melanoma have seen ipilimumab registered as an 
approved therapy for patients with metastatic disease on the 
basis of a positive phase-3 trial.33
Although our study was initiated to characterize the 
lymphomas that inadvertently developed during xenograft 
implantations, we have also discovered an unexpected associ-
ation with clinical outcome that was independent of mutations 
in the EGFR and KRAS genes. These tumors were human, of 
B-cell lineage, and EBV positive despite the primary tumors 
being negative and not heavily infiltrated by lymphocytes. 
Although we are unable to conclusively prove our hypothesis, 
these results suggest that a robust immune repertoire that was 
not only active against latent viral infection, but also poten-
tially could respond to antigens expressed by tumors, was pres-
ent and active within the host when the tumor was removed. 
These observations provide further support for current stud-
ies evaluating various ways to stimulate immune responses in 
patients with NSCLC.
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